Cell and Gene Therapy Investment Trends
Cell and Gene Therapy Investment Trends with Pete Bak, PhD Kyle O’Neil and Brendan Wang Cell and gene therapies are currently among the hottest investments in the biotech space, both in the public and private markets. In this episode, Back Bay’s Managi
Back Bay Life Science Report · Pete Bak, PhD
Audio is streamed directly from the publisher (media.transistor.fm) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Cell and gene therapies are currently among the hottest investments in the biotech space, both in the public and private markets. In this episode, Back Bay’s Managing Director and host Pete Bak, PhD is joined by Kyle O’Neil and Brendan Wang, who are returning to the podcast after attending the 2021 Cell and Gene Meeting on the Mesa. Tune in to hear their discussion on emerging investment themes and which ones were key topics of discussion at this year’s conference.
Topics include:
- The next generation of gene-editing technology
- CRISPR 2.0
- Off-target effects
- Novel nucleases
- PAM sequences
- Autologous and Allogeneic CAR-T cell therapy
- Ex vivo vs. in vivo approaches
- The business model on gene therapies
- Figuring out manufacturing capabilities first
- How to tap into larger markets
- Building businesses around small monogenic diseases
Learn more, read Bay Life Science Advisors' latest white paper on gene therapy innovation here.
Make sure to subscribe to The Life Science Report podcast and follow Back Bay Life Science Advisors on LinkedIn.
Thank you for joining us.